Yang Bo, Lu Ping, Li Mei-Xuan, Cai Xiao-Ling, Xiong Wan-Yuan, Hou Huai-Jing, Ha Xiao-Qin
Department of Clinical Laboratory, The People's Liberation Arimy Joint Service Support Unit 940 Hospital.
School of Clinical Medicine, Gansu University of Traditional Chinese Medicine (TCM), Lanzhou.
Medicine (Baltimore). 2019 Sep;98(37):e16618. doi: 10.1097/MD.0000000000016618.
This meta-analysis assessed the effectiveness of probiotics and synbiotics for acute diarrhea (AD) in children and investigated probiotic formulations, types of interventions, and country factors.
Randomized, double-blind, placebo-controlled trials evaluating the effects of probiotics or synbiotics on AD were analyzed. We followed the recommendations of the Cochrane Handbook and the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement. The risks of systematic errors (bias) and random errors were assessed, and the overall quality of the evidence was evaluated using the Grades of Recommendations Assessment, Development, and Evaluation (GRADE) approach.
The meta-analysis included 34 studies with 4911 patients. Five and 29 studies presented the results of synbiotic and probiotic interventions, respectively. After intervention, the durations of diarrhea (weighted mean difference (WMD) = -16.63 [-20.16; -12.51]) and hospitalization (risk ratio (RR) = 0.59 [0.48; 0.73]) were shorter, the stool frequency on day 3 (WMD = -0.98 [-1.55; -0.40]) was decreased, and the incidence of diarrhea lasting 3 days was lower in the probiotic and synbiotic groups than in the control groups. Furthermore, in the subgroup analyses, synbiotics were more effective than probiotics at reducing the durations of diarrhea and hospitalization, and Saccharomyces and Bifidobacterium were more effective than Lactobacillus at reducing the duration of diarrhea.
This meta-analysis supports the potential beneficial roles of probiotics and synbiotics for AD in children. Further research is needed to determine problems associated with probiotic/synbiotic mixtures and appropriate dosages.
本荟萃分析评估了益生菌和合生制剂对儿童急性腹泻(AD)的疗效,并研究了益生菌制剂、干预类型和国家因素。
分析了评估益生菌或合生制剂对AD疗效的随机、双盲、安慰剂对照试验。我们遵循了Cochrane手册和系统评价与荟萃分析优先报告项目(PRISMA)声明的建议。评估了系统误差(偏倚)和随机误差的风险,并使用推荐分级评估、制定和评价(GRADE)方法评估了证据的整体质量。
该荟萃分析纳入了34项研究,共4911例患者。分别有5项和29项研究呈现了合生制剂和益生菌干预的结果。干预后,益生菌组和合生制剂组的腹泻持续时间(加权平均差(WMD)=-16.63[-20.16;-12.51])和住院时间(风险比(RR)=0.59[0.48;0.73])缩短,第3天的排便频率(WMD=-0.98[-1.55;-0.40])降低,腹泻持续3天的发生率低于对照组。此外,在亚组分析中,合生制剂在缩短腹泻持续时间和住院时间方面比益生菌更有效,酿酒酵母和双歧杆菌在缩短腹泻持续时间方面比乳酸杆菌更有效。
本荟萃分析支持益生菌和合生制剂对儿童AD的潜在有益作用。需要进一步研究以确定与益生菌/合生制剂混合物相关的问题和合适的剂量。